- Home
- DEC vs SLS Comparison
DEC vs SLS Comparison
Compare DEC & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DEC | SLS |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.5M | 924.5M |
| IPO Year | 2022 | 2007 |
Fundamental Metrics
Financial Performance| Metric | DEC | SLS |
|---|---|---|
| Price | $13.07 | $8.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $22.29 | $10.00 |
| AVG Volume (30 Days) | 809.8K | ★ 9.0M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.09% | N/A |
| EPS Growth | ★ 311.06 | 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,829,142,000.00 | N/A |
| Revenue This Year | $26.53 | N/A |
| Revenue Next Year | N/A | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 141.54 | N/A |
| 52 Week Low | $12.33 | $1.39 |
| 52 Week High | $18.90 | $9.51 |
Technical Indicators
Market Signals| Indicator | DEC | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 32.91 | 55.24 |
| Support Level | $12.52 | $7.07 |
| Resistance Level | $13.46 | $9.51 |
| Average True Range (ATR) | 0.46 | 0.66 |
| MACD | -0.09 | -0.16 |
| Stochastic Oscillator | 16.28 | 44.27 |
Price Performance
Historical ComparisonAbout DEC Diversified Energy Company plc
Diversified Energy Co engaged in the production, transportation, and marketing of natural gas, NGLs, and oil, managing a diversified portfolio of mature, long-life assets located across the United States. The company derives revenues from the sale of oil, natural gas and natural gas liquids.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.